How did a bad batch of heroin change our understanding of Parkinson’s disease? 

Explore the Uncommon Connections series to hear unusual stories behind some of history’s greatest medical breakthroughs and learn how uncommon connections between unexplained symptoms can lead to surprising diagnoses in rare diseases.

Visit the episode website for full notes, including references and legal information, or visit the Uncommon Connections channel to listen to this episode and more. 

Access free diagnostic testing for your patients. 

Note: Sanofi Campus is intended for healthcare professionals only.

References:

1. Langston JW. The MPTP Story. J Parkinsons Dis 2017: S11–S19. 


2. Pycroft L et al. Deep brain stimulation: An overview of history, methods, and future developments. Brain Neurosci Adv 2018; 2: 1–6. 


3. Schwalb JM and Hamani C. The history and future of deep brain stimulation. Neurotherapeutics 2008; 5: 3–13. 


4. Weingarten HL. 1-Methyl-4-Phenyl-I,2,3,6-Tetrahydropyridine (MPTP): one Designer drug and serendipity. J Forensic Sci 1988; 33(2): 588–95. 

sanofi-aventis australia pty ltd trading as Sanofi. ABN 31 008 558 807. Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. 

MAT-AU-2102037. Date of preparation: November 2022. 2200475.

See omnystudio.com/listener for privacy information.